Copy
CANCER CLINICAL TRIALS NEWSLETTER
Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination with Docetaxel vs Placebo in Combination with Docetaxel in Subjects with NSCLC

A randomized, double-blind, placebo-controlled trial of docetaxel with either canakinumab or a placebo dosed intravenously every 3 weeks in patients with NSCLC previously treated with PDL1 inhibitors and platinum based chemotherapy without success. 

Determining hBD-3 as a valid biomarker in head and neck cancer

This is an umbrella study using tissue samples from consent to the UCCI-UMB-14-01 protocol. Oral saliva samples will be used to replicate the human beta defensin index's ability to distinguish oral squamous cell carcinoma(OSCC) from non-cancerous lesions.

Click Here to Download All Cancer Trials Open to Accrual
Questions?  Please call us at 513-584-7698, or email us!
UC Scientist Discovers What Makes Tumors Grow and Multiply

Scientists are studying the feeding mechanism important for tumor growth by targeting the energy production mechanism of cancerous cells. 
Click Here to Visit the UC Newsroom
SAVE THE DATE
Gastrointestinal Cancer CME Event


Saturday, March 28, 2020  | 7:30 a.m.–1:30 p.m.
The Manor House  |  7440 Mason Montgomery Rd Mason, OH 45040


For more information or questions, email kelly.hummel@uc.edu, or call 513-558-2030.
 
Division of Hematology Oncology Grand Rounds Schedule
Facebook
Twitter
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
natalie.ciulla@uc.edu






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UCCI Clinical Trials · 200 Albert Sabin Way Ste 4002A · Ml 0502 · Cincinnati, OH 45267-0502 · USA